WILMINGTON, N.C., & CONSHOHOCKEN, Penn.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD) and ePharmaSolutions today announced that their strategic alliance has been recognized with a Microsoft 2013 Life Sciences Innovation Award, honoring their initiatives in integrating world-leading clinical research expertise and eClinical solutions to advance biopharmaceutical clients’ research programs.
Through PPD’s alliance with ePharmaSolutions, a leading clinical services and eClinical solutions provider, PPD clients and investigative sites benefit from innovative new enterprise tools that enable faster and easier site feasibility and study start-up, study training, site management, and patient recruitment and engagement.
Microsoft recognized ePharmaSolutions’ PatientLive™ and PPD® PatientView, two online portal applications that provide access to the Microsoft HealthVault™ personal health record solution. PPD and ePharmaSolutions’ collaboration covers a suite of innovative portal technologies, also including:
- PPD® SponsorView, providing PPD clients easy online access to trial-related documents, key reports, metrics and other vital information.
- PPD® SiteView, enhancing connectivity among research sites, PPD and sponsors and featuring regulatory document collection with training, contact information and site closeout details, along with central access to other key systems, such as electronic data capture.
Microsoft honored PPD and ePharmaSolutions June 25 in Boston at the 49th annual meeting of the Drug Information Association (DIA). The Microsoft Life Sciences Innovation Awards recognize companies using Microsoft solutions to realize business and information technology benefits and revolutionize medicine by bringing therapeutic breakthroughs to the market faster to fight serious ailments, improve health care and enhance patients’ quality of life.
ePharmaSolutions’ PatientLive™ matches patients to clinical trials using a geo-therapeutic matching algorithm and opt-in intelligent profiles to alert patients about trials for which they may qualify to improve patient engagement and the opportunity to participate in a trial. PPD PatientView links clinical trial participants with clinical research sites, biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve patient retention in trials.
“This recognition demonstrates the value of our strategic relationship with ePharmaSolutions and the time and cost efficiencies our clients gain in conducting clinical trials,” said Mike Wilkinson, PPD’s chief information officer and executive vice president. “Our collaboration leverages PPD’s people, processes and technologies to help investigative sites and biopharmaceutical companies streamline their R&D programs in a fast-evolving clinical research environment.”
Lance Converse, founder and chief executive officer of ePharmaSolutions, said: “PPD is an innovative organization looking to meet the needs of its clients. Our integrated platform enables easy-to-use collaboration capabilities, secure document exchange and learning management as a core component of PPD’s enterprise environment designed for process efficiency, compliance and reliability.”
About PPD
PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 12,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.
About ePharmaSolutions
ePharmaSolutions is a leading provider of eClinical solutions that help improve the way trial sites are selected, trained, activated and managed to exceed enrollment goals. ePharmaSolutions has won multiple Bio-IT World Awards for best clinical trial technology and has activated and trained more than 300,000 clinical researchers in 130 countries for the top 20 pharmaceutical companies and CROs in the world. ePharmaSolutions is headquartered in Philadelphia with offices in Slough, UK. For more information, visit www.epharmasolutions.com or email info@epharmasolutions.com.
Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about the Microsoft Life Sciences Innovation Awards and the partnership between PPD and ePharmaSolutions, contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: rapid technological advances that make our services less competitive; competition in the outsourcing industry; the ability to attract, integrate and retain key personnel; compliance with drug development regulations; changes in the regulation of the drug development process; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; consolidation in the pharmaceutical and biotechnology industries; PPD’s ability to win new business; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; actual operating performance; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; and the ability to control SG&A spending. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.
